Emyria Valuation Multiples

Emyria is valued at $25M as of October 2026, a 5.3x revenue multiple. In the last 12 months, Emyria revenue was $4M and Emyria EBITDA was ($4M).

Emyria Overview

About Emyria

Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.


Founded

2018

HQ

Australia

Employees

N/A

Website

emyria.com

Financials (LTM)

Revenue: $4M
EBITDA: ($4M)

EV

$21M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Emyria Financials

Emyria reported last 12-month revenue of $4M and negative EBITDA of ($4M).

In the same LTM period, Emyria generated ($4M) in gross profit, ($4M) in EBITDA losses, and had net loss of ($5M).

Revenue (LTM)


Emyria P&L

In the most recent fiscal year, Emyria reported revenue of $909K and EBITDA of ($2M).

Emyria is unprofitable as of last fiscal year, with gross margin of (5%), EBITDA margin of (195%), and net margin of (240%).

See analyst estimates for Emyria
LTMLast FY202320242025202620272028
Revenue$4M$909K$1M$1M$2M
Gross Profit($4M)($42K)($292K)($82K)($2M)
Gross Margin(101%)(5%)(21%)(7%)(98%)
EBITDA($4M)($2M)($5M)($5M)($3M)
EBITDA Margin(106%)(195%)(399%)(373%)(148%)
EBIT Margin(114%)(356%)(369%)(329%)(194%)
Net Profit($5M)($2M)($6M)($5M)($3M)
Net Margin(118%)(240%)(437%)(416%)(172%)
Net Debt-($2M)---

Financial data powered by Morningstar, Inc.

Emyria Stock Performance

Emyria has current market cap of $25M, and enterprise value of $21M.

Market Cap Evolution


Emyria's stock price is $0.03.

Emyria share price decreased by 3.1% in the last 30 days, and by 7.3% in the last year.

See more trading valuation data for Emyria
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$21M$25M-0.0%-3.1%-2.3%-7.3%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Emyria Valuation Multiples

Emyria trades at 5.3x EV/Revenue multiple, and (5.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Emyria

EV / Revenue (LTM)


Emyria Financial Valuation Multiples

As of October 5, 2026, Emyria has market cap of $25M and EV of $21M.

Emyria has a P/E ratio of (5.4x).

LTMLast FY202320242025202620272028
EV/Revenue5.3x22.8x15.2x16.4x10.9x
EV/EBITDA(5.0x)(11.7x)(3.8x)(4.4x)(7.3x)
EV/EBIT(4.6x)(6.4x)(4.1x)(5.0x)(5.6x)
EV/Gross Profit(5.2x)n/m(70.7x)n/m(11.1x)
P/E(5.4x)(11.6x)(4.2x)(4.8x)(7.7x)
EV/FCF(5.2x)(10.6x)(4.6x)(7.0x)(7.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Emyria Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Emyria Margins & Growth Rates

Emyria grew revenue by 219% and EBITDA by 118% in the last fiscal year.

In the most recent fiscal year, Emyria reported gross margin of (5%), EBITDA margin of (195%), and net margin of (240%).

See estimated margins and future growth rates for Emyria

Emyria Margins

Last FY202420252026202720282029
Gross Margin(5%)(7%)(98%)(87%)
EBITDA Margin(195%)(373%)(148%)(91%)
EBIT Margin(356%)(329%)(194%)(98%)
Net Margin(240%)(416%)(172%)(101%)
FCF Margin(215%)(235%)(140%)(87%)

Emyria Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth219%(7%)51%154%
Gross Profit Growth8598%(72%)2172%124%
EBITDA Growth118%(14%)(40%)56%
EBIT Growth28%(18%)(11%)28%
Net Profit Growth101%(12%)(37%)49%
FCF Growth67%(34%)(10%)58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Emyria Operational KPIs

Emyria's Rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Emyria's Rule of X is 293% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Emyria
LTMLast FY202320242025202620272028
Rule of 4012%62%---
Bessemer Rule of X189%293%---
G&A Expenses to Revenue-72%69%68%36%
R&D Expenses to Revenue9%47%102%77%21%
Opex to Revenue-351%348%323%173%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Gesundheitswelt Chiemgau$93M$9M0.6x-5.9x-
Clinica de Marly------
Maternus-Kliniken$133M$5M1.7x-49.1x-
Sudmedica$167K($293K)215.4x-(122.5x)-
Eukedos$60M$13M2.0x-9.4x-
Concord Medical Services$69M($12M)15.4x-(86.8x)-
MedNation$60M$6M0.4x-3.9x-
Speed Medical SAE------

This data is available for Pro users. Sign up to see all Emyria competitors and their valuation data.

Start Free Trial

Emyria VC Funding History

Before going public, Emyria raised $4M in total equity funding, across 1 round.


Emyria Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-21Strategic investmentTattarang$4M-Tattarang made a A$5 million strategic placement into ASX-listed Emyria, subscribing for 20 million new shares at A$0.25 each plus 10 million options and taking roughly 7.3 per cent of the Perth drug developer. The funds were directed at Emyria's synthetic cannabinoid registration programs with the Therapeutic Goods Administration and the US Food and Drug Administration. Emyria combines its Emerald Clinics patient network and real-world data registry with its own product development, and Tattarang framed the placement as backing a Western Australian medical innovator.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Emyria

When was Emyria founded?Emyria was founded in 2018.
Where is Emyria headquartered?Emyria is headquartered in Australia.
Is Emyria publicly listed?Yes, Emyria is a public company listed on Australian Securities Exchange.
What is the stock symbol of Emyria?Emyria trades under EMD ticker.
When did Emyria go public?Emyria went public in 2020.
Who are competitors of Emyria?Emyria main competitors include Gesundheitswelt Chiemgau, Clinica de Marly, Maternus-Kliniken, Sudmedica, Eukedos, Concord Medical Services, MedNation, Speed Medical SAE, Amwill Healthcare, Constance Care.
What is the current market cap of Emyria?Emyria's current market cap is $25M.
What is the current revenue of Emyria?Emyria's last 12 months revenue is $4M.
What is the current revenue growth of Emyria?Emyria revenue growth (NTM/LTM) is 118%.
What is the current EV/Revenue multiple of Emyria?Current revenue multiple of Emyria is 5.3x.
Is Emyria profitable?No, Emyria is not profitable.
What is the current EBITDA of Emyria?Emyria has negative EBITDA and is not profitable.
What is Emyria's EBITDA margin?Emyria's last 12 months EBITDA margin is (106%).
What is the current EV/EBITDA multiple of Emyria?Current EBITDA multiple of Emyria is (5.0x).
What is the current FCF of Emyria?Emyria's last 12 months FCF is ($4M).
What is Emyria's FCF margin?Emyria's last 12 months FCF margin is (102%).
What is the current EV/FCF multiple of Emyria?Current FCF multiple of Emyria is (5.2x).
How many companies Emyria has acquired to date?Emyria hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Emyria has invested to date?Emyria hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Emyria

Lists including Emyria

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial